Last reviewed · How we verify

Lynparza (olaparib)

AstraZeneca · FDA-approved active Verified Quality 73/100

Lynparza blocks the repair of DNA damage in cancer cells by inhibiting the enzyme PARP.

Lynparza (olaparib) is a small molecule Poly(ADP-Ribose) Polymerase Inhibitor developed by AstraZeneca, targeting Poly [ADP-ribose] polymerase 2. It was FDA-approved in 2014 for various cancer indications, including BRCA mutation-positive breast and ovarian cancers. Lynparza is patented and has no generic manufacturers. Key safety considerations include myelosuppression, nausea, and fatigue. It is a targeted therapy that works by blocking the repair of DNA damage in cancer cells.

At a glance

Generic nameolaparib
SponsorAstraZeneca
Drug classPoly(ADP-Ribose) Polymerase Inhibitor [EPC]
TargetPoly [ADP-ribose] polymerase 2
Therapeutic areaOncology
PhaseFDA-approved
First approval2014
Annual revenue2600

Mechanism of action

Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular functions, such as DNA transcription and DNA repair. Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mouse xenograft models of human cancer, both as monotherapy or following platinum-based chemotherapy. Increased cytotoxicity and anti-tumor activity following treatment with olaparib were noted in cell lines and mouse tumor models with deficiencies in BRCA1/2, ATM, or other genes involved in the homologous recombination repair (HRR) of DNA damage and correlated with platinum response. In vitro studies have shown that olaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes, resulting in DNA damage and cancer cell death.

Approved indications

Common side effects

Key clinical trials

Patents

PatentExpiryType

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results
FDA Orange BookPatents + exclusivity
SEC EDGARRevenue + earnings

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: